All Stories

  1. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom

    Article • Current Medical Research and Opinion, April 2023, Taylor & Francis

    Dr Michael D L Smyth

  2. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review

    Article • Osteoporosis International, July 2020, Springer Science + Business Media

    Dr Michael D L Smyth

  3. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study

    Article • Orphanet Journal of Rare Diseases, June 2020, Springer Science + Business Media

    Dr Michael D L Smyth

  4. Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience

    Article • Gastroenterology Report, August 2019, Oxford University Press (OUP)

    Dr Michael D L Smyth

  5. The number needed to treat and relevant between-trial comparisons of competing interventions

    Article • ClinicoEconomics and Outcomes Research, December 2018, Dove Medical Press

    Dr Michael D L Smyth

  6. Corrigendum: Exposure—efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease

    Article • Journal of Crohn s and Colitis, January 2018, Oxford University Press (OUP)

    Dr Michael D L Smyth

  7. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease

    Article • Digestive and Liver Disease, October 2017, Elsevier

    Dr Michael D L Smyth

  8. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom

    Article • The European Journal of Health Economics, March 2017, Springer Science + Business Media

    Dr Michael D L Smyth

  9. Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease

    Article • Journal of Crohn s and Colitis, February 2017, Oxford University Press (OUP)

    Dr Michael D L Smyth

  10. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

    Article • Clinical Gastroenterology and Hepatology, February 2017, Elsevier

    Dr Michael D L Smyth

  11. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis

    Article • PLOS One, October 2016, PLOS

    Dr Michael D L Smyth

  12. Long-term Efficacy of Vedolizumab for Crohn’s Disease

    Article • Journal of Crohn s and Colitis, September 2016, Oxford University Press (OUP)

    Dr Michael D L Smyth

  13. Long-term Efficacy of Vedolizumab for Ulcerative Colitis

    Article • Journal of Crohn s and Colitis, September 2016, Oxford University Press (OUP)

    Dr Michael D L Smyth

  14. Corrigendum to “Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6” [J Crohns Colitis 8S1 (2014) P497 S274-5]

    Article • Journal of Crohn s and Colitis, October 2014, Oxford University Press (OUP)

    Dr Michael D L Smyth

  15. Long-Term Efficacy of Vedolizumab Therapy for Crohn’s Disease: Presidential Poster

    Article • The American Journal of Gastroenterology, October 2014, Wolters Kluwer Health

    Dr Michael D L Smyth

  16. P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    Dr Michael D L Smyth

  17. Results of a Pilot Program to Improve Phosphorus Outcomes in Hemodialysis Patients

    Article • Journal of Renal Nutrition, September 2012, Elsevier

    Dr Michael D L Smyth

  18. Lanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding

    Article • Renal Failure, January 2012, Taylor & Francis

    Dr Michael D L Smyth

  19. Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective

    Article • Value in Health, December 2011, Elsevier

    Dr Michael D L Smyth

  20. Comparison of Dietary Phosphate Absorption After Single Doses of Lanthanum Carbonate and Sevelamer Carbonate in Healthy Volunteers: A Balance Study

    Article • American Journal of Kidney Diseases, May 2011, Elsevier

    Dr Michael D L Smyth

  21. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol

    Article • Nephrology Dialysis Transplantation, October 2010, Oxford University Press (OUP)

    Dr Michael D L Smyth

  22. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy

    Article • Current Medical Research and Opinion, October 2009, Taylor & Francis

    Dr Michael D L Smyth

  23. A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report

    Article • Nephrology Dialysis Transplantation, September 2009, Oxford University Press (OUP)

    Dr Michael D L Smyth

  24. Comment on: 'Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis'

    Article • Clinical Kidney Journal, March 2009, Oxford University Press (OUP)

    Dr Michael D L Smyth

  25. Letter regarding ‘advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate’

    Article • Kidney International, August 2008, Elsevier

    Dr Michael D L Smyth